UnknownNot Applicable

Hypoxia-induced Autophagy in the Pathogenesis of MAP

80 participantsStarted 2023-09

Plain-language summary

To investigate the role of HIF 1α and LC3B in the pathogenesis of MAP, to evaluate the role of MMP-9 in the antenatal prediction of MAP, and to compare the expression of HIF1α, LC3B, and level MMP-9 between patients of placenta previa with MAP and patients with normal placentation.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Gestational age: more than 28 weeks up to 40 weeks.
✓. Pregnant women with at least one previous CS.
✓. Singleton pregnancy.
✓. Patient known to have placenta previa by 2D ultrasound.
✓. Heamodynamically stable patient.

Exclusion criteria

✕. Multiple pregnancy.
✕. Gestational age less than 28 weeks.
✕. Heamodynamically unstable patient.
✕. Hypertensive disorder with pregnancy.
✕. Gestational diabetes.
✕. IUGR.
✕. Patient with bleeding tendency or using anticoagulant.

What they're measuring

Compare the expression of HIF 1α and LC3B by immunohistochemistry and the level of MMP-9

Timeframe: 28-40 weeks of gestation.

Trial details

NCT IDNCT05817448

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-09

Contact for this trial

Nermeen Bahaa ElDien Mohamed Ahmed, dr

01011126294 nermeenbahaa11@gmail.com

View on ClinicalTrials.gov More Hypoxia trials